Healthcare Realty Trust Incorporated HR
Healthcare Realty Trust operates as a Real Estate Investment Trust (REIT), specializing in the acquisition, development, financing, and active management of income-generating real estate assets, predominantly serving outpatient healthcare providers throughout the United States. By September 30, 2020, its extensive portfolio comprised 211 properties located across 24 states, collectively spanning 15.5 million square feet and valued at approximately $5.5 billion. The company further provided comprehensive leasing and property management solutions for 11.9 million square feet nationwide.
Business overview written from the company's own Form 10-K (Item 1), filed 2026-02-13 — refreshed whenever it files a new one. The figures above are current; see its SEC filings. ✓ From the 10-K
Plain-English: the Snapshot is the quick read — what it pays you (yield, dividend), how its cash flow looks (FFO/AFFO, Price/OCF) and how much debt it carries. Switch to Expert in the header to hide these explanations.
Snapshot
Reported FFO / AFFO / leverage are from the Q1 2026 earnings release (filed 2026-04-30) — 8-K, EX-99.1 ✓ Verified to filing.
Yield uses the latest declared dividend, annualized (latest regular payout × frequency; special/liquidating distributions excluded) — an announced-but-not-yet-declared change isn't reflected until it has an ex-date. FFO, AFFO and Net debt / Adj. EBITDA are the company's reported figures from its latest earnings 8-K. Price/OCF and payout use GAAP operating cash flow. NAV premium and credit ratings have no free source yet. See Methodology.
$10,000 invested
Illustrative income only, at today's price and latest declared dividend — it excludes price changes, dividend cuts and taxes. Not a forecast.
Model HR yourself — any amount, shares, per-payment & a multi-year DRIP projection →
Balance sheet (latest FY: 2025)
Debt-maturity ladder, fixed/floating split, secured/unsecured and coverage ratios come from the supplemental — not yet ingested.
Financial history
| FY | Revenue | Net income | D&A | EBITDA | Op. cash flow |
|---|---|---|---|---|---|
| 2025 | $1.18B | $-246.07M | $563.97M | $519.96M | $457.10M |
| 2024 | $1.27B | $-654.49M | $675.15M | $266.62M | $501.62M |
| 2023 | $1.34B | $-278.26M | $730.71M | $717.28M | $499.82M |
| 2022 | $932.64M | $40.90M | $453.08M | $635.71M | $272.75M |
| 2021 | $534.82M | $66.66M | $202.71M | $321.90M | $232.63M |
| 2020 | $735.07M | $52.62M | $303.83M | $357.34M | $470.09M |
Dividends
Recent regular dividends per share (special distributions excluded), oldest → newest.
| Ex-date | Record | Payment | Declared | Amount | Freq. |
|---|---|---|---|---|---|
| 2026-05-11 | 2026-05-11 | 2026-05-22 | 2026-04-30 | $0.24 | Quarterly |
| 2026-02-24 | 2026-02-24 | 2026-03-11 | 2026-02-12 | $0.24 | Quarterly |
| 2025-11-10 | 2025-11-11 | 2025-11-21 | 2025-10-30 | $0.24 | Quarterly |
| 2025-08-14 | 2025-08-14 | 2025-08-28 | 2025-07-31 | $0.24 | Quarterly |
| 2025-05-12 | 2025-05-12 | 2025-05-23 | 2025-05-01 | $0.31 | Quarterly |
| 2025-03-03 | 2025-03-03 | 2025-03-19 | 2025-02-19 | $0.31 | Quarterly |
| 2024-11-12 | 2024-11-12 | 2024-11-27 | 2024-10-29 | $0.31 | Quarterly |
| 2024-08-12 | 2024-08-12 | 2024-08-28 | 2024-07-30 | $0.31 | Quarterly |
| 2024-05-10 | 2024-05-13 | 2024-05-23 | 2024-04-30 | $0.31 | Quarterly |
| 2024-02-23 | 2024-02-26 | 2024-03-14 | 2024-02-13 | $0.31 | Quarterly |
| 2023-11-13 | 2023-11-14 | 2023-11-30 | 2023-10-30 | $0.31 | Quarterly |
| 2023-08-14 | 2023-08-15 | 2023-08-30 | 2023-08-01 | $0.31 | Quarterly |
| 2023-05-15 | 2023-05-16 | 2023-06-02 | 2023-05-02 | $0.31 | Quarterly |
| 2023-03-06 | 2023-03-07 | 2023-03-21 | 2023-02-24 | $0.31 | Quarterly |
| 2022-11-14 | 2022-11-15 | 2022-11-30 | 2022-11-02 | $0.31 | Quarterly |
| 2022-08-12 | 2022-08-15 | 2022-08-30 | 2022-08-03 | $0.11 | Monthly |
| 2022-07-21 | 2022-07-19 | 2022-07-27 | 2022-07-06 | $4.82 | Special |
| 2022-07-13 | 2022-07-14 | 2022-07-19 | 2022-07-01 | $0.03 | Irregular |
| 2022-07-05 | 2022-07-06 | 2022-07-15 | 2022-05-05 | $0.33 | Quarterly |
| 2022-05-13 | 2022-05-03 | 2022-05-27 | 2022-05-03 | $0.31 | Quarterly |
| 2022-04-01 | 2022-04-04 | 2022-04-11 | 2022-02-28 | $0.33 | Monthly |
| 2022-02-25 | 2022-02-22 | 2022-03-15 | 2022-02-22 | $0.31 | Irregular |
| 2022-01-03 | 2022-01-04 | 2022-01-11 | 2021-11-04 | $0.33 | Irregular |
| 2021-11-12 | 2021-11-02 | 2021-11-30 | 2021-11-03 | $0.30 | Quarterly |
Coverage (payout of operating cash flow): 73.47%. Tax-character split (ordinary / 199A / capital gain / return of capital) — not disclosed (requires the annual allocation release).
Recent news — HR
Healthcare Realty Trust Announces Second Quarter Earnings Release Date and Conference Call
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
New Strong Buy Stocks for June 8th
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
Healthcare Realty Trust: Betting On Outpatient Demand Growth, Lower Operator Risk (Upgrade)
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
Headlines via Financial Modeling Prep; links open the original publisher in a new tab. Not an endorsement or investment advice.
Other Health Care REITs
Same-store NOI, occupancy, leasing/WALT, top tenants, external-manager fees, development pipeline and (for non-traded vehicles) share-class fees, redemption/gating and NAV methodology are planned modules sourced from supplementals and prospectuses.